Aprea Therapeutics, Inc. (APRE)

$3.8

+0.36 (+10.47%)
Rating:
Recommendation:
-
Symbol APRE
Price $3.8
Beta 0.000
Volume Avg. 0.01M
Market Cap 14.180M
Shares () -
52 Week Range 0.474-25.8
1y Target Est -
DCF Unlevered APRE DCF ->
DCF Levered APRE LDCF ->
ROE -1457.11% Strong Sell
ROA -725.75% Strong Sell
Operating Margin -
Debt / Equity 12.48% Neutral
P/E -0.07 Neutral
P/B 0.25 Neutral
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest APRE news


Dr. Oren Gilad Ph.D.
Healthcare
Biotechnology
NASDAQ Global Select

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.